Patisiran and vutrisiran are other FDA-approved RNA therapies to prevent TTR synthesis in individuals with hereditary transthyretin amyloidosis and were designed as small double-stranded RNAis with lipid NPs and GaINAc delivery particles, respectively [186,187]. This evidence concerns the gene TTR and prealbumin measurement.